CollPlant Biotechnologies

Expanding Distribution And Pipeline Advances Will Open New Markets

AnalystConsensusTarget

Not Invested

Consensus Narrative from 1 Analyst

Published

27 Apr 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

US$12.00

83.6% undervalued

15 Aug

US$1.97

-59.5%

-27.7%

Author's Valuation

US$12.0

83.6% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on01 May 25

AnalystConsensusTarget Fair Value

US$12.0

83.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

36.02%

Biotech revenue growth rate

12.78%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.34%

Calculation

US$1.41m

Earnings '28

129.91x

PE Ratio '28

US$183.10m

Market Cap '28

US$183.10m

Market Cap '28

11.45m

No. shares '28

US$15.98

Share Price '28

US$15.98 Share Price '28

Discounted to 2025 @ 8.34% p.a.

US$12.57

Fair Value '25